Short-Course Radiation Therapy Proves Effective for Endometrial Cancer

Recent findings from a clinical trial conducted by researchers at the Huntsman Cancer Institute in Utah have demonstrated that a short-course, higher-dose vaginal brachytherapy treatment for endometrial cancer is as effective as the traditional approach involving multiple lower-dose sessions. This advancement could significantly impact treatment protocols for individuals diagnosed with this type of cancer.

The trial, known as the SAVE (Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared with Standard of Care), has been documented in the journal JCO Oncology Advances. The study aimed to determine optimal dosing and scheduling for brachytherapy, addressing a notable gap in existing research that has led to varied clinical practices.

Endometrial cancer, which originates in the lining of the uterus, is primarily treated through surgical methods, including the removal of the uterus, cervix, and upper portion of the vagina. Following surgery, brachytherapy is employed as a secondary treatment to reduce the risk of cancer recurrence. This technique involves administering internal radiation via an applicator placed in the vaginal cavity.

In the SAVE trial, two groups of patients were compared: one received the standard treatment involving three to five sessions of lower doses, while the other received a higher radiation dose over just two sessions. The results indicated that the short-course treatment yielded similarly effective short-term results with minimal acute side effects.

According to the lead researcher, the outcomes of this trial are expected to enhance cancer care for patients across the Mountain West region, particularly for those in rural and frontier areas. Traveling for treatment can be a significant challenge for these patients, and the findings from the SAVE trial may alleviate some of this burden while maintaining effective disease management.

One of the study's co-developers highlighted the increasing incidence of endometrial cancer, which is now recognized as the most common cancer affecting the female reproductive system. The trial received participation from multiple esteemed institutions, and its success is credited to the cooperation and support from clinical colleagues and the patients who took part in the research.

Overall, the findings from the SAVE trial underscore the potential for more efficient treatment regimens in managing endometrial cancer, paving the way for improved patient outcomes and accessibility to care.